If approved, Mavenclad could offer a more patient-friendly ... is taken twice daily and is associated with unpleasant gastrointestinal side-effects. But Merck KGaA’s drug requires two short ...
Merck KGaA’s Mavenclad (cladribine) tablets have been recommended by the National Institute for Health and Care Excellence (NICE) to treat a broader group of multiple sclerosis (MS) patients. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback